Unlock instant, AI-driven research and patent intelligence for your innovation.

A new crystal of ticagrelor and its preparation method

A ticagrelor and crystallization technology, which is applied in the field of ticagrelor new crystallization and its preparation, can solve the problems of high toxicity of chloroform as a crystallization solvent, unsuitable for large-scale production, uneven crystal particles, and the like, and saves the preparation preparation process. , excellent stability, simple preparation method

Active Publication Date: 2019-06-14
CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD +1
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Among the above-mentioned crystal forms, type II crystal has the best stability, and it is also the crystal form of the drug marketed by the original research unit, but the crystallization solvent of type II crystal, chloroform, is highly toxic and is not suitable for large-scale production; and the crystal particles are not uniform, There are large particles, which need to be pulverized first when preparing the preparation, and the cost of the preparation is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A new crystal of ticagrelor and its preparation method
  • A new crystal of ticagrelor and its preparation method
  • A new crystal of ticagrelor and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Embodiment 1: Preparation of ticagrelor crystals

[0065] Add 10g of crude ticagrelor (reference Bioorganic & Medicinal Chemistry Letters 22 (2012) 3598~3602, purity 98%) and 80mL ethyl acetate into the reaction flask, heat to 55±5°C, stir to dissolve, keep at the same temperature , add 40mL of n-hexane dropwise, solid precipitates out, keep stirring at the same temperature for 2h, then cool down to 15~30°C, continue stirring for 1h, filter and dry to obtain 9.1g of white crystalline solid with HPLC purity of 99.6%. Small crystalline particles, fluffy appearance, low viscosity. Get the obtained crystalline sample and carry out XRD detection, the results are shown in Table 1, and the spectrum is shown in the attached figure 1 . In addition, the obtained crystallization samples were taken for particle size detection, the results are shown in Table 2, and the spectrograms are shown in the attached figure 2 .

[0066] Table 1 Example 1 obtained ticagrelor crystalline p...

Embodiment 2~5

[0071] Embodiment 2~5: Preparation of ticagrelor crystals

[0072] Referring to the preparation method of Example 1, the crystallization conditions were changed, and the experimental results are shown in Table 3.

[0073] Table 3 Embodiment 2~5 experimental results

[0074] .

[0075] Table 4 The characteristic peak data of ticagrelor crystal powder X-ray diffraction obtained in Example 2-5

[0076] .

[0077] It can be seen from the experimental results in Table 2 that all the preparation methods of the present invention can obtain the new crystals of ticagrelor of the present invention.

Embodiment 6

[0078] Embodiment 6: Preparation of ticagrelor crystals

[0079] Add 10g of crude ticagrelor (reference Bioorganic & Medicinal Chemistry Letters 22 (2012) 3598~3602, purity 98%) and 60mL ethyl acetate into the reaction flask, heat to 55±5°C, stir to dissolve, add dropwise quickly ( Add 60mL of n-hexane below 25℃ at a drop rate of about 10mL / min, quickly cool down in an ice bath to 15~30℃ (about 5~10min), stir for 4h, filter, and dry to obtain ticagrelor crystals 9.4g, HPLC purity 99.6%. Get the obtained crystallization sample and carry out XRD detection, the results are shown in Table 3, and the obtained collection of patterns is shown in the attached image 3 . In addition, the obtained crystallization sample is taken for particle size detection, and the results are shown in Table 6, and the obtained collection of illustrative plates is shown in the attached Figure 4 .

[0080] Table 5 The characteristic peak data of ticagrelor crystal powder X-ray diffraction obtained i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The present invention discloses a ticagrelor new crystal and a preparation method thereof. The ticagrelor new crystal powder X-ray diffraction shows a strongest peak at 2 theta for 5.7 + / -0.2 degree, and teh particle size d (0.9) is less than 30 mum. The ticagrelor new crystal is stable in quality, stable in crystal form, small particle size and uniform in distribution, the preparation procedure is saved, the production cost is reduced, and the ticagrelor new crystal is more suitable for use as a raw material medicine; a solvent used in the preparation method is cheap, easy to get, and less in toxicity, and is more suitable for large scale production.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a new crystal of ticagrelor and a preparation method thereof. Background technique [0002] Ticagrelor, chemical name (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]- 5-(thiopropyl)-3H-[1,2,3]triazol[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2 -diol, the structural formula is as shown in formula 1: [0003] [0004] 1. [0005] Ticagrelor belongs to the cyclopentyl triazolopyrimidine compound and is a new type of selective small molecule anticoagulant drug developed by Astra Zenica. The drug can reversibly act on the purine 2 receptor subtype P2Y on vascular smooth muscle cells 12 , has obvious inhibitory effect on platelet aggregation caused by ADP, and takes effect quickly after oral administration, so it can effectively improve the symptoms of patients with acute coronary heart disease. And because the antiplatelet effect ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D487/04A61K31/519A61P7/02
CPCC07B2200/13C07D487/04
Inventor 周付刚张雅然马玉秀刘洋刘晓争道硕
Owner CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD